Fig 1: Survival: a Kaplan-Meier survival curve showing the association between DAXX protein expression and overall survival (OS) for 398 patients with survival data. Patients with effusions with high (> 25%) DAXX expression (n = 180; red line) had mean OS of 35.3 months compared to 44.8 months for patients with effusions having low (= 25%) DAXX expression (n = 218, blue line; p = 0.014). b Kaplan-Meier survival curve showing the association between ATRX protein expression and OS for 398 patients with survival data. Patients with effusions with high (> 25%) ATRX expression (n = 306; red line) had mean OS of 40.5 months compared to 39.6 months for patients with effusions having low (= 25%) ATRX expression (n = 92, blue line; p = 0.710.7133). c Kaplan-Meier survival curve showing the association between patient age and OS for 398 patients with survival data. Older (> 60 years) patients (n = 234; red line) had mean OS of 37.6 months compared to 45 months for younger (= 60 years) patients (n = 164, blue line; p = 0.019). d Kaplan-Meier survival curve showing the association between FIGO stage and OS for 386 patients with survival data and FIGO stage III–IV disease. Patients diagnosed with stage IV disease (n = 151; red line) had mean OS of 31.1 months compared to 45.2 months for patients with stage III disease (n = 235, blue line; p < 0.001). e Kaplan-Meier survival curve showing the association between residual disease (RD) volume and OS for 210 patients who received surgery as upfront treatment. Patients debulked to no macroscopic disease (n = 31; blue line) had mean OS of 59.7 months compared to 46.6 and 44.8 months for patients debulked to 1 cm (n = 86, red line) and = 2 cm (n = 93, green line), respectively (p = 0.201). f Kaplan-Meier survival curve showing the association between RD volume and OS for 109 patients who received neoadjuvant chemotherapy prior to debulking surgery. Patients debulked to no macroscopic disease (n = 30; blue line) had mean OS of 50.7 months compared to 37.9 and 25.1 months for patients debulked to 1 cm (n = 48; red line) and = 2 cm (n = 31; green line), respectively (p = 0.005). g Kaplan-Meier survival curve showing the association between DAXX protein expression and OS for 261 patients with pre-chemotherapy effusions and survival data. Patients with effusions with high (> 25%) DAXX expression (n = 108; red line) had mean OS of 36.2 months compared to 46.4 months for patients with effusions having low (= 25%) DAXX expression (n = 153, blue line; p = 0.038)